Efficacy of topical ivermectin and impact on quality of life in patients with papulopustular rosacea: A systematic review and meta‐analysis

Abstract

Rosacea is a chronic dermatosis which affects negatively patients' quality of life (QoL).There is shortage of high-quality evidence comparing the efficacy of ivermectin cream (IVM) 1% with other available topical choices. Besides, the well-documented impaired of self-esteem and stigmatization of rosacea patients make essential to address which treatment provides the greatest psychological and social benefit. Our objective is to critically review and appraise the efficacy of IVM 1% in PPR and the impact in patients' QoL against other options. We carried out a literature search from PubMed, MEDLINE, EMBASE, Cochrane, and clinicaltrials.gov using the following descriptors:"rosacea" AND "ivermectin." Efficacy was assessed with the Investigator Global Assessment (IGA), and the impact on QoL was based on the DLQI score. Six studies from four published articles were included. The meta-analysis estimated that more participants achieved "success" (IGA ≤ 1) and "complete clearance" (IGA = 0) with IVM1%. The overall effect estimate for IGA ≤ 1 was: 1.56 [1.23-1.97], whereas for IGA = 0, it was: 1.72 [1.40-2.11]. The rate of participants achieving lower DLQI score, and thus, better QoL was with IVM 1%. The overall effect estimate was: 1.71 [1.34-2.18] at week 16# and 1.64 [1.38-1.94] at week 52#. This meta-analysis confirms IVM 1% cream as the most effective topical treatment and it satisfies the impairment of social life with sustained better QoL. Further studies extending this period of remission are warranted, as well as researches about the potential application of this agent combined with other agents. KEY POINTSQuestion: What is the current efficacy of ivermectin versus other choices in papulopustular rosacea and its impact on patients' quality of life?Findings: In this meta-analysis, ivermectin showed higher efficacy than metronidazol, azelaic acid, and placebo measured by Investigator Global Assessment. Parallely, the DLQI score highlighted that this agent was more beneficious in both short and long-term.Meaning: This meta-analysis gives strong evidence that ivermectin is the most effective topical treatment. Besides, this agent provides the greatest psychological benefit

COVID‐19 related masks increase severity of both acne (maskne) and rosacea (mask rosacea): Multi‐center, real‐life, telemedical, and observational prospective study

“…Laboratory results further support the clinical findings, since in our study severity scores and DLQI worsened in both acne and rosacea patients after 6 weeks of masks, in agreement with previous reports described a detrimental influence on quality of life in patients affected by these dermatoses 24,25 …”

Rosacea Treatment: Review and Update

“…Topical azelaic acid (high-certainty evidence), topical ivermectin (high-certainty evidence), topical metronidazole (moderate-certainty evidence), and topical minocycline (moderate-certainty evidence) were recommended for the treatment of papules/pustules [19]. In a systematic review and meta-analysis, topical ivermectin was demonstrated to be the most effective topical treatment for papulopustular rosacea and to provide the greatest psychological benefit to these patients [29]. Topical ivermectin can be applied not only to skin almost clear of papulopustular rosacea or with mild rosacea, but also to skin with moderate to severe rosacea [4].…”

Evaluation of the efficacy of subantimicrobial dose doxycycline in rosacea: a systematic review of clinical trials and meta‐analysis

“…In a recent meta-analysis, topical ivermectin 1 % was mentioned as the best topical approach for PPR [14]. Ivermectin has a dual effect on PPR, by inhibiting critical pathways of the inflammatory response and reducing the density of the Demodex mite [49], and topical ivermectin 1 % has been Figure 3 Results of the overall meta-analysis including comparative studies of SDD versus placebo and studies of SDD versus active drugs (a).…”